TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By In8Bio, Inc.
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IN8bio reported financial results and highlighted preclinical data on INB-619, a novel gamma-delta T cell engager, demonstrating potential for deep B cell depletion with minimal adverse effects. The company expanded its INB-100 Phase 1 clinical trial to The Ohio State University and continues advancing its T cell therapy platform.

Insights
MSFT   neutral

Mentioned as a cloud computing competitor with 20% market share


INAB   positive

Company showed promising preclinical data, expanded clinical trial, reduced expenses, and maintained a strategic focus on developing innovative T cell therapies